RxDoctor Payments Data

Patricia Danaher, MD

Family Medicine · Lockport, NYNPI 1861439879

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 178 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$414
  • AstraZeneca$380
  • Lilly USA, LLC$324
  • AbbVie$319
  • Astellas Pharma US Inc$313
  • Boehringer Ingelheim$249
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,07994%
  • Education$1826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,261 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$52,419
Medicare patients
136
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$23,202
JardianceEmpagliflozin15$20,561
EliquisApixaban20$18,580
Rosuvastatin Calcium46$1,038
Levothyroxine Sodium66$975
Metoprolol Succinate44$854
Oxybutynin Chloride ErOxybutynin Chloride16$817
Atorvastatin Calcium58$728
Albuterol Sulfate HfaAlbuterol Sulfate15$557
Alendronate Sodium45$486
Gabapentin26$458
Metformin Hcl ErMetformin Hcl13$403
Omeprazole22$400
Famotidine22$396
Duloxetine Hcl12$389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$23,20223 claims
Boehringer IngelheimJardiance$249$20,56115 claims
PfizerEliquis$204$18,58020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Lockport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →